摘要
目的 探究同步放化疗联合尼妥珠单抗靶向治疗局部晚期鼻咽癌的疗效及对血清表皮生长因子样结构域7(EGFL7)水平、氧化应激的影响。方法 选择2017-2020年初茂名市人民医院收治的97例局部晚期鼻咽癌患者,按照随机数字表法分为实验组(n=49)和对照组(n=48),对照组进行同步放化疗,实验组在对照组基础上联合尼妥珠单抗靶向治疗,比较两组近期疗效、血清EGFL7水平、氧化应激反应水平[超氧化物歧化酶(SOD),丙二醛(MDA),一氧化氮(NO)]和不良反应。随访3年,采用Kaplan-Meier法绘制生存曲线。结果 放化疗结束3个月后,实验组鼻咽部原发灶、颈部淋巴结缓解率均高于对照组,差异有统计学意义(χ^(2)=4.521、4.990,P<0.05);治疗后两组血清EGFL7及SOD水平均降低,NO、MDA均升高,且实验组血清EGFL7、NO、MDA水平低于对照组,SOD水平高于对照组,差异有统计学意义(t=3.052、3.945、5.364、2.422,P<0.05);两组口腔黏膜炎、血红蛋白下降、血小板下降等不良反应发生率比较,差异无统计学意义(P>0.05);实验组3年无进展生存率、总生存率高于对照组,差异有统计学意义(χ^(2)=5.907、5.315,P<0.05),两组3年复发率比较,差异无统计学意义(P>0.05)。结论 放化疗联合尼妥珠单抗靶向治疗能提高局部晚期鼻咽癌近期疗效和远期生存率,降低血清EGFL7和氧化应激水平,且不良反应轻可耐受。
Objective To explore the effect of concurrent chemoradiotherapy combined with Nimotuzumab targeted therapy in locally advanced nasopharyngeal carcinoma and on epidermal growth factor-like domain 7(EGFL7)levels and oxidative stress.Methods A total of 97 patients with locally advanced nasopharyngeal carcinoma admitted to Maoming People ’ s Hospital from 2017 to early 2020 were selected and divided into experimental group(n=49)and control group(n=48)according to the random number table method.The control group received concurrent chemoradiotherapy,and the experimental group was supplemented with nimotuzumab targeted therapy on the basis of the control group.The short-term efficacy,serum EGFL7 levels,oxidative stress levels[superoxide dismutase(SOD),malondialdehyde(MDA),nitric oxide(NO)]and adverse reactions were compared between the two groups.Followed up for 3 years,the Kaplan-Meier method was used to draw the survival curve.Results Three months after the chemoradiotherapy,the remission rates of primary nasopharyngeal lesions and cervical lymph nodes in the experimental group were higher than those in the control group(χ^(2)=4.521,4.990,P<0.05).After treatment,the serum EGFL7 and SOD levels of the two groups decreased,NO and MDA increased,and the serum EGFL7,NO,MDA levels of the experimental group were lower than those of the control group,but the SOD level was higher than that of the control group(t=3.052,3.945,5.364,2.422,P<0.05).There were no significant differences in the incidence of adverse reactions such as oral mucositis,decreased hemoglobin,and decreased platelets between the two groups(P>0.05).The 3-year progression-free survival rate and the overall survival rate of the experimental group were higher than those of the control group (χ^(2)=5.907,5.315,P<0.05).There was no significant difference in the 3-year recurrence rate between the two groups(P>0.05).Conclusion Concurrent chemoradiotherapy combined with Nimotuzumab targeted therapy could improve the short-term efficacy and long-term survival rate
作者
陆小玲
林华明
麦大海
黎昌国
黄毅超
李文
江璧锋
LU Xiao-ling;LIN Hua-ming;MAI Da-hai;LI Chang-guo;HUANG Yi-chao;LI Wen;JIANG Bi-feng(Department of Oncology,Maoming People's Hospital,Maoming,Guangdong 525000,China)
出处
《热带医学杂志》
CAS
2022年第2期230-234,共5页
Journal of Tropical Medicine
基金
茂名市科技计划项目(190408101701597)。
关键词
放化疗
尼妥珠单抗
鼻咽癌
EGFL7
Chemoradiotherapy
Nimotuzumab
Nasopharyngeal carcinoma
EGFL7
